Advice

in the absence of a submission from the holder of the marketing authorisation:

ibrutinib (Imbruvica®) is not recommended for use within NHSScotland.

Indication under review: In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Download detailed advice355KB (PDF)

Download

Medicine details

Medicine name:
ibrutinib (Imbruvica)
SMC ID:
SMC2244
Indication:

In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.

Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Submission type
Non submission
Status
Not recommended
Date advice published:
11 November 2019